Skip to main content
. Author manuscript; available in PMC: 2019 Aug 27.
Published in final edited form as: Oncogene. 2017 Oct 30;37(8):1020–1030. doi: 10.1038/onc.2017.392

Figure 6. Inflammatory signaling that is suppressed by MYB is required for lung metastasis.

Figure 6

(a) Meta-analyses of BCs patients available on KMplot.com representing the probability of distant metastasis free survival in BCs stratified according to the expression status of the signature genes (CCL2, CXCL1, CXCL2, CXCL6, CXCL16, ICAM1, IL1A, TNFRSF9, LCN2, IKBKE and inversed MYB). The log-rank test P value reflects the significance of the correlation between inflammatory gene signature high/MYB low and shorter survival outcome. b-c) Kaplan–Meier plots showing lung metastasis-free, bone metastasis-free and other metastasis-free (liver/LN) survival of BCs patients from datasets: GSE260351 and GSE1227652, respectively. Survival analysis based on MYB expression (b) and based on signature enrichment (defined in A) as determined by z-score (c). Signature enriched = samples with significant up-regulation of the signature; signature not-enriched = the rest of samples (d) Model of the Myb-repressed inflammatory circuit during pulmonary metastasis.